Structure of Cetirizine 2HCl
CAS No.: 83881-52-1
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Cetirizine 2HCl, a metabolite of hydroxyzine, is racemic selective and inverse agonist of H1 receptor used in the treatment of allergies and hay fever.
Synonyms: P071; Cetirizine (hydrochloride); UCB-P 071
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
| CAS No. : | 83881-52-1 |
| Formula : | C21H27Cl3N2O3 |
| M.W : | 461.81 |
| SMILES Code : | O=C(COCCN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(Cl)C=C3)O.[H]Cl.[H]Cl |
| Synonyms : |
P071; Cetirizine (hydrochloride); UCB-P 071
|
| MDL No. : | MFCD00941428 |
| InChI Key : | PGLIUCLTXOYQMV-UHFFFAOYSA-N |
| Pubchem ID : | 55182 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302 |
| Precautionary Statements: | P280-P305+P351+P338 |
| Target |
|
In Vitro:
| Concentration | Treated Time | Description | References |
| Murine eosinophils cultured from bone marrow | 5 μM | 30 minutes | To measure the inhibitory effect of cetirizine on eosinophil degranulation, results showed cetirizine significantly reduced EPO release. | J Clin Invest. 2013;123(5):2306-2316. |
| Guinea-pig ventricular myocytes | 0.1 μM | 10 minutes | Cetirizine at 0.1 μM reduced IKr to 49%, while IKs was only inhibited to 79%. | Br J Pharmacol. 1998 Jun;124(4):663-8. |
| Rabbit ventricular myocytes | 0.1 μM | 10 minutes | To analyze the effect of cetirizine on delayed K+ currents, results showed cetirizine inhibited IKr current with an IC50 of 108 μM. | Br J Pharmacol. 1998 Jun;124(4):663-8. |
In Vivo:
| Administration | Dosage | Frequency | Description | References |
| Mice | NMO model | Oral | 10 mg/kg | Twice daily for 3 days | To study the inhibitory effect of cetirizine on NMO lesions, results showed cetirizine significantly reduced lesion severity and eosinophil infiltration. | J Clin Invest. 2013;123(5):2306-2316. |
| Balb/C mice | Ovalbumin-sensitized peritonitis model | Subcutaneous injection | 15-30 mg/kg | 1 hour before and 6 hours after | Cetirizine significantly reduced ovalbumin-induced eosinophil accumulation, whereas terfenadine was ineffective, suggesting that the effect of cetirizine was not related to the inhibition of the H1 receptor effects of histamine. | Br J Pharmacol. 1993 Oct;110(2):917-24 |
| Male Wistar rats | PAF or compound 48/80-induced pleural eosinophil accumulation model | Intraperitoneal or intrathoracic | 5 to 30 mg/kg (i.p.) or 5 and 15 μg/cavity (i.t.) | Single dose, 1 h before (i.p.) or 5 min before (i.t.) | To evaluate the inhibitory effect of cetirizine on PAF or compound 48/80-induced pleural eosinophil accumulation, results showed that cetirizine significantly inhibited eosinophil accumulation, and this effect was not related to its antagonism of histamine H1 receptors. | Br J Pharmacol. 1992 Jan;105(1):176-80. |
| Guinea-pigs | Ovalbumin-sensitized paw oedema model | Subcutaneous injection | 20 mg/kg | Single dose, measured 30 minutes after administration | To evaluate the inhibitory effect of cetirizine on ovalbumin-induced paw oedema, results showed cetirizine was ineffective | Br J Pharmacol. 1994 May;112(1):111-6 |
| C57BL/6J male mice | DMM-induced osteoarthritis model | Oral gavage | 100μg/day | Once daily for 12 weeks | To evaluate the effect of cetirizine on the development of osteoarthritis in the DMM mouse model. Results showed that cetirizine significantly attenuated cartilage degeneration and reduced the expression of OA-related mediator genes. | Clin Immunol. 2022 Nov;244:109117 |
| DBA/2 mice | Viral myocarditis model | Oral | 1 or 10 mg/kg/day | Once daily, starting on the day of viral inoculation | Cetirizine improved survival dose dependently, significantly decreased the heart weight to body weight ratio, reduced the area of myocardial necrosis, and suppressed the gene expressions of tumor necrosis factor, interleukin 6, and metalloproteinase 2. | J Inflamm (Lond). 2010 Aug 4;7:39 |
| Guinea pigs | Non-immunized guinea pigs receiving platelets from immunized animals | Intravenous injection | 10-30 mg/kg | Administered 1 hour before antigen challenge | Cetirizine dose-dependently inhibited platelet-dependent leucopenia, with the highest dose achieving complete inhibition. Terfenadine and mepyramine were ineffective. | Br J Pharmacol. 1991 Jun;103(2):1520-4 |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT00628108 | Allergic Rhinitis ... More >> Chronic Urticaria Less << | Phase 3 | Completed | - | United States, Alabama ... More >> Birmingham, Alabama, United States United States, Arkansas Hot Springs, Arkansas, United States Jonesboro, Arkansas, United States Little Rock, Arkansas, United States United States, California Bakersfield, California, United States Crescent City, California, United States Huntington Beach, California, United States Los Angeles, California, United States Orange, California, United States Roseville, California, United States Stockton, California, United States United States, Georgia Albany, Georgia, United States Gainesville, Georgia, United States United States, Illinois Normal, Illinois, United States United States, Missouri Bridgeton, Missouri, United States United States, Nebraska Omaha, Nebraska, United States United States, Oklahoma Oklahoma City, Oklahoma, United States United States, South Carolina Barnwell, South Carolina, United States Spartanburg, South Carolina, United States United States, Tennessee Kingsport, Tennessee, United States United States, Texas Austin, Texas, United States Dallas, Texas, United States El Paso, Texas, United States San Antonio, Texas, United States Sugarland, Texas, United States United States, Virginia Richmond, Virginia, United States Less << |
| NCT00521131 | Rhinitis Alle... More >>rgic Perennial Less << | Phase 4 | Completed | - | - |
| NCT00520754 | Cough | Phase 2 | Completed | - | - |
| NCT00628108 | - | Completed | - | - | |
| NCT00557284 | Atopic Dermatitis | Phase 4 | Completed | - | United States, Colorado ... More >> 1st Allergy & Clinical Research Centers Centennial, Colorado, United States, 80112 1st Allergy & Clinical Research Centers Thornton, Colorado, United States, 80229 Less << |
| NCT01567501 | Fed | Phase 1 | Completed | - | India ... More >> Accutest Research Lab (I) Pvt. Ltd. Ahmedabad, Gujarat, India, 380054 Less << |
| NCT01557439 | Fasting State | Phase 1 | Completed | - | India ... More >> Accutest Research Lab (I) Pvt. Ltd. Ahmedabad, Gujarat, India, 380054 Less << |
| NCT00557284 | - | Completed | - | - | |
| NCT02583594 | Progressive Multiple Sclerosis | Phase 1 | Active, not recruiting | April 2021 | Spain ... More >> Investigational Site Number 724001 Barcelona, Spain, 08035 Less << |
| NCT03590912 | Otitis Media With Effusion | Phase 4 | Not yet recruiting | September 2019 | Nepal ... More >> Lumbini Medical College Tansen, Palpa, Nepal, 32500 Less << |
| NCT00001910 | - | Completed | - | United States, Maryland ... More >> National Institute of Allergy and Infectious Diseases (NIAID) Bethesda, Maryland, United States, 20892 Less << | |
| NCT02771249 | Healthy Volunteers | Phase 1 | Recruiting | December 31, 2019 | United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov Less << |
| NCT03523221 | Mild -Moderate Anaphylaxis - S... More >>ymptoms That Affect the Skin With Cardiovascular, Respiratory or Gastrointestinal Involvement, But no Signs of Hypotension ,Laryng Less << | Phase 1 | Recruiting | August 2020 | Qatar ... More >> Hamad Medical Corporation Recruiting Doha, Qatar, 3050 Contact: Rafah Sayyed, MD +97455747045 ralsayyed@hamad.qa Less << |
| NCT02646904 | Allergic Rhinitis | Phase 4 | Completed | - | Italy ... More >> Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council Palermo, Sicily, Italy, 90146 Institute of Biomedicine and Molecular Immunology, IBIM Palermo, Italy, 90146 Less << |
| NCT03296358 | Urticaria All... More >>ergy Less << | Not Applicable | Recruiting | October 31, 2019 | Thailand ... More >> Chulalongkorn Hospital Recruiting Pathum Wan, Bangkok, Thailand, 10600 Contact: Pakhawadee Palungwachira, Bachelor 66897704758 zaphyr_s@yahoo.com Principal Investigator: Pakhawadee Palungwachira, Bachelor Sub-Investigator: Katsara Vilaisri, Bachelor Sub-Investigator: Klongwong Musikatavorn, Bachelor Less << |
| NCT02873364 | Urticaria | Phase 3 | Unknown | January 2017 | Iran, Islamic Republic of ... More >> Shiraz University of Medical Sciences Recruiting Shiraz, Fars, Iran, Islamic Republic of Contact: Keramatallah Jahanshahi, MD +989177416523 kjahanshahi91@gmail.com Less << |
| NCT00561717 | Seasonal Allergic Rhinitis | Phase 4 | Completed | - | Canada, Ontario ... More >> Kingston, Ontario, Canada, K7L 2V7 Less << |
| NCT02613910 | - | Terminated(Novartis has acquir... More >>ed the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.) Less << | - | - | |
| NCT01241214 | Seasonal Allergic Rhinitis | Phase 2 | Completed | - | United States, Texas ... More >> Clinical Investigative Site 7905 Austin, Texas, United States, 78731 Clinical Investigative Site 7907 Kerrville, Texas, United States, 78028 Clinical Investigative Site 7903 New Braunfels, Texas, United States, 78130 Clinical Investigative Site 7901 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7902 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7904 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7906 San Antonio, Texas, United States, 78229 Less << |
| NCT01451996 | Healthy | Phase 4 | Completed | - | United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 Less << |
| NCT02613910 | Pemphigus | Phase 3 | Terminated(Novartis has acquir... More >>ed the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.) Less << | - | United States, California ... More >> GSK Investigational Site Los Angeles, California, United States, 90045 United States, Michigan GSK Investigational Site Ann Arbor, Michigan, United States, 48103 Less << |
| NCT01451996 | - | Completed | - | - | |
| NCT01985789 | Asthma | Phase 4 | Completed | - | Canada, Saskatchewan ... More >> University of Saskatchewan Saskatoon, Saskatchewan, Canada, S7N 0W8 Less << |
| NCT01940393 | Urticaria | Phase 4 | Completed | - | Colombia ... More >> Medellin Medellin, Antioquia, Colombia Less << |
| NCT01134328 | Allergic Conjunctivitis | Phase 2 | Completed | - | United States, Massachusetts ... More >> Ora, Inc Andover, Massachusetts, United States, 01810 Less << |
| NCT01902836 | Childhood Atopic Dermatitis | Phase 2 | Completed | - | Mexico ... More >> Hospital Infantil de México, Fedérico Gómez México, DF, Mexico, 06720 Less << |
| NCT01981499 | Migraine | Phase 1 | Terminated(The trial was prema... More >>turely terminated on 01April2014 due to safety concerns.) Less << | - | United States, Minnesota ... More >> Pfizer Investigational Site St. Paul, Minnesota, United States, 55114 Less << |
| NCT01134328 | - | Completed | - | - | |
| NCT02535416 | Healthy | Phase 1 | Completed | - | Australia, Queensland ... More >> QPharm, Pty Limited, Royal Brisbane Hospital Herston, Queensland, Australia, 4029 Less << |
| NCT00517946 | - | Completed | - | United Kingdom ... More >> GSK Investigational Site London, United Kingdom, W1G 8HU Less << | |
| NCT02535416 | - | Completed | - | - | |
| NCT02024152 | Acute Urticaria | Phase 1 | Completed | - | Canada, Quebec ... More >> Algorithme Pharma Montreal, Quebec, Canada Less << |
| NCT01008592 | - | Terminated(Mediators of intere... More >>st were not consistently detectable with the analytical methods employed.) Less << | - | United States, North Carolina ... More >> Wake Forest University Health Sciences, Department of Dermatology Winston-Salem, North Carolina, United States, 27157 Less << | |
| NCT01318681 | Seasonal Allergic Rhinitis ... More >> Driving Ability Cognition Less << | Not Applicable | Completed | - | Netherlands ... More >> Maastricht University Maastricht, Limburg, Netherlands, 62ooMD Less << |
| NCT00533637 | Allergic Rhinitis | Phase 2 | Completed | - | Sweden ... More >> Department of Otorhinolaryngology, Lund University Hospital Lund, Sweden, SE-221 85 Less << |
| NCT01068223 | Histamine Induced Itch | Phase 1 | Completed | - | United Kingdom ... More >> Harrow, United Kingdom Less << |
| NCT01484119 | Seasonal Allergic Rhinitis | Phase 3 | Completed | - | United States, Texas ... More >> Clinical Investigative Site 7905 Austin, Texas, United States, 78731 Clinical Investigative Site 7907 Kerrville, Texas, United States, 78028 Clinical Investigative Site 7903 New Braunfels, Texas, United States, 78130 Clinical Investigative Site 7901 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7902 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7904 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7906 San Antonio, Texas, United States, 78229 Less << |
| NCT02451579 | Actinic Keratoses | Not Applicable | Completed | - | United States, California ... More >> Cosmetic Laser Dermatology San Diego, California, United States, 92121 Less << |
| NCT02935699 | Acute Urticaria | Phase 3 | Recruiting | April 2018 | United States, Texas ... More >> City Doc Urgent Care center Recruiting Dallas, Texas, United States, 75209 Contact: Brook Jackson Canada, Ontario Ottawa Hospital Recruiting Ottawa, Ontario, Canada, K1Y 4E9 Contact: Cathy Clement Less << |
| NCT00974571 | - | Completed | - | - | |
| NCT00610584 | Seasonal Allergic Rhinitis | Not Applicable | Completed | - | Germany ... More >> Charité - Institute for Social Medicine Berlin, Germany, 10098 Less << |
| NCT00291642 | Rhinitis Alle... More >>rgic Seasonal Less << | Phase 2 | Completed | - | Canada, Ontario ... More >> Kingston, Ontario, Canada Less << |
| NCT00851344 | Rhinitis, Allergic, Seasonal | Phase 2 | Completed | - | Germany ... More >> GSK Investigational Site Hannover, Niedersachsen, Germany, 30625 Less << |
| NCT03167216 | Chronic Prostatitis With Chron... More >>ic Pelvic Pain Syndrome Less << | Early Phase 1 | Recruiting | June 30, 2021 | United States, Illinois ... More >> Northwestern Medical Faculty Foundation Recruiting Chicago, Illinois, United States, 60611 Principal Investigator: Praveen Thumbikat, PhD Less << |
| NCT00974571 | Perennial Allergic Rhinitis | Phase 3 | Completed | - | - |
| NCT01825655 | Pruritus | Phase 4 | Terminated(Unable to recruit p... More >>atients) Less << | - | United States, Virginia ... More >> Children's Hospital of Richmond at VCU Richmond, Virginia, United States, 23298 Less << |
| NCT01825655 | - | Terminated(Unable to recruit p... More >>atients) Less << | - | - | |
| NCT00544388 | Rhinitis, Allergic, Seasonal | Phase 3 | Completed | - | - |
| NCT02447393 | Dermatitis | Phase 1 | Completed | - | Japan ... More >> GSK Investigational Site Kagoshima, Japan, 890-0081 Less << |
| NCT00291642 | - | Completed | - | - | |
| NCT00972504 | Rhinitis, Allergic, Seasonal | Phase 2 | Completed | - | Germany ... More >> GSK Investigational Site Hannover, Niedersachsen, Germany, 30625 Less << |
| NCT01495338 | Normal Ocular Health | Phase 1 | Completed | - | United States, Massachusetts ... More >> Andover Eye Associates Andover, Massachusetts, United States, 01810 Less << |
| NCT00474890 | Atopy Rhiniti... More >>s Less << | Not Applicable | Completed | - | Germany ... More >> Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Germany, 30625 Less << |
| NCT00257595 | Rhinitis, Allergic, Perennial | Phase 3 | Completed | - | - |
| NCT01322282 | Allergy | Phase 1 | Completed | - | Canada, Quebec ... More >> Algorithme Pharma Inc. Mount-Royal, Quebec, Canada, H3P 3P1 Less << |
| NCT00420082 | Seasonal Allergic Rhinitis | Phase 2 | Completed | - | Austria ... More >> Allergy Center Vienna West Vienna, Austria, A-1150 Less << |
| NCT00972504 | - | Completed | - | - | |
| NCT03192488 | Exercise Intolerance at Altitu... More >>de Less << | Phase 4 | Recruiting | May 31, 2018 | United States, Indiana ... More >> Indiana University Recruiting Bloomington, Indiana, United States, 47401 Contact: Robert Chapman, PhD 812-856-2452 rfchapma@indiana.edu Less << |
| NCT01651871 | Seasonal Allergic Rhinitis | Phase 2 | Completed | - | - |
| NCT00334698 | Seasonal Allergic Rhinitis | Not Applicable | Completed | - | Germany ... More >> Fraunhofer-Institute of Toxicology and Experimental Medicine Hannover, Germany, 30623 Less << |
| NCT01103050 | Allergic Rhinitis | Phase 2 | Completed | - | Canada ... More >> Novartis Investigative Site Ontario, Canada Less << |
| NCT00257569 | Dermatitis, Atopic | Phase 3 | Completed | - | - |
| NCT02543346 | Allergic Rhinitis | Phase 4 | Completed | - | United States, Texas ... More >> Biogenics Research Chamber San Antonio, Texas, United States, 78229 Canada, Ontario Kingston General Hospital Kingston, Ontario, Canada, K7L 2V7 Less << |
| NCT03047278 | Neuropathic Pain ... More >> Type 2 Diabetes Mellitus Diabetic Neuropathy, Painful Less << | Phase 4 | Enrolling by invitation | July 1, 2019 | - |
| NCT01748344 | Seasonal Allergic Rhinitis | Phase 2 | Completed | - | Austria ... More >> Vienna Clinical Site Vienna, Austria Less << |
| NCT00253058 | Rhinitis, Allergic, Perennial | Phase 3 | Completed | - | - |
| NCT00751218 | Urticaria | Phase 4 | Completed | - | - |
| NCT00751166 | Urticaria | Phase 4 | Terminated(Study could not be ... More >>re-supplied with study medication in a timely manner.) Less << | - | - |
| NCT00504933 | Seasonal Allergic Rhinitis | Phase 3 | Completed | - | - |
| NCT01127620 | Perennial Allergic Rhinitis | Phase 3 | Completed | - | - |
| NCT00637455 | Seasonal Allergic Rhinitis | Phase 4 | Completed | - | United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less << |
| NCT00240032 | Multiple Sclerosis | Phase 4 | Completed | - | - |
| NCT01622283 | Rhinitis, Allergic, Perennial ... More >>and Seasonal Less << | Phase 1 | Completed | - | Japan ... More >> GSK Investigational Site Kagoshima, Japan, 890-0081 Less << |
| NCT00881634 | Allergies | Phase 1 | Completed | - | - |
| NCT00257582 | Pruritus | Phase 3 | Completed | - | - |
| NCT00150761 | Anti-allergic Agents | Phase 4 | Completed | - | - |
| NCT00488176 | Seasonal Allergic Rhinitis | Phase 4 | Unknown | December 2013 | Poland ... More >> Department of Pediatrics and Allergy, Medical University of Lodz Lodz, Poland Recruiting Lodz, Poland, 93-513 Contact: Violetta Ścibiorek, MD 00 48 42 689 59 72 alergol@kopernik.lodz.pl Principal Investigator: Iwona Stelmach, MD, PhD, Prof Less << |
| NCT00650065 | Healthy | Phase 1 | Completed | - | United States, Texas ... More >> Novum Pharmaceutical Research Services Houston, Texas, United States, 77042 Less << |
| NCT00826943 | Allergic Rhinitis | Phase 4 | Completed | - | United States, Tennessee ... More >> Vanderbilt University Asthma, Sinus, and Allergy Clinic Nashville, Tennessee, United States, 37203 Less << |
| NCT00826943 | - | Completed | - | - | |
| NCT00881127 | Allergies | Phase 1 | Completed | - | - |
| NCT01551056 | Allergic Conjunctivitis | Phase 3 | Completed | - | United States, Massachusetts ... More >> Ora, Inc. Andover, Massachusetts, United States, 01810 Less << |
| NCT02173249 | Healthy | Phase 1 | Completed | - | United States, Massachusetts ... More >> Andover Eye Associates Andover, Massachusetts, United States, 01810 Less << |
| NCT01551056 | - | Completed | - | - | |
| NCT01685242 | Allergic Conjunctivitis | Phase 3 | Completed | - | United States, Massachusetts ... More >> Andover Eye Associates Andover, Massachusetts, United States, 01810 Less << |
| NCT01685242 | - | Completed | - | - | |
| NCT01881113 | Allergic Conjunctivitis | Phase 3 | Completed | - | United States, Massachusetts ... More >> Ora, Inc. Andover, Massachusetts, United States, 01810 Less << |
| NCT00639587 | Rhinitis, Allergic, Perennial | Phase 3 | Completed | - | - |
| NCT01916226 | Rhinitis, Allergic, Perennial ... More >>and Seasonal Less << | Phase 4 | Completed | - | - |
| NCT00375713 | Dermatitis Ec... More >>zema Less << | Phase 3 | Completed | - | Korea, Republic of ... More >> Gyeunggi-do, Korea, Republic of Kyeonggi-Do, Korea, Republic of Seoul, Korea, Republic of Less << |
| NCT01881113 | - | Completed | - | - | |
| NCT00375713 | - | Completed | - | - | |
| NCT02756624 | Healthy Subjects | Phase 3 | Completed | - | United States, Massachusetts ... More >> Ora Clinical Site Network Andover, Massachusetts, United States, 01810 Less << |
| NCT00490204 | Rhinitis, Allergic, Perennial | Phase 3 | Completed | - | Japan ... More >> GSK Investigational Site Chiba, Japan, 277-0882 GSK Investigational Site Fukuoka, Japan, 807-0856 GSK Investigational Site Fukuoka, Japan, 811-1201 GSK Investigational Site Fukuoka, Japan, 819-0002 GSK Investigational Site Hokkaido, Japan, 001-0923 GSK Investigational Site Hokkaido, Japan, 007-0840 GSK Investigational Site Hokkaido, Japan, 053-0833 GSK Investigational Site Hokkaido, Japan, 061-1133 GSK Investigational Site Hokkaido, Japan, 061-1448 GSK Investigational Site Hokkaido, Japan, 062-0034 GSK Investigational Site Kanagawa, Japan, 212-0027 GSK Investigational Site Kanagawa, Japan, 213-0011 GSK Investigational Site Kanagawa, Japan, 216-0002 GSK Investigational Site Kanagawa, Japan, 222-0011 GSK Investigational Site Kanagawa, Japan, 224-0003 GSK Investigational Site Kanagawa, Japan, 232-0056 GSK Investigational Site Kumamoto, Japan, 862-0952 GSK Investigational Site Kumamoto, Japan, 862-0962 GSK Investigational Site Oita, Japan, 870-0021 GSK Investigational Site Saitama, Japan, 333-0861 GSK Investigational Site Saitama, Japan, 336-0022 GSK Investigational Site Saitama, Japan, 350-1205 GSK Investigational Site Saitama, Japan, 355-0062 GSK Investigational Site Shizuoka, Japan, 420-0803 GSK Investigational Site Shizuoka, Japan, 422-8066 GSK Investigational Site Shizuoka, Japan, 436-0058 GSK Investigational Site Tokyo, Japan, 157-0067 GSK Investigational Site Tokyo, Japan, 170-0005 Less << |
| NCT02756624 | - | Completed | - | - | |
| NCT01332188 | Allergic Conjunctivitis | Phase 2 Phase 3 | Completed | - | United States, Massachusetts ... More >> Ora, Inc. Andover, Massachusetts, United States, 01810 Less << |
| NCT00649857 | Healthy | Phase 1 | Completed | - | United States, Texas ... More >> Novum Pharmaceutical Research Services Houston, Texas, United States, 77042 Less << |
| NCT01916226 | - | Completed | - | - | |
| NCT01332188 | - | Completed | - | - | |
| NCT00794378 | Allergic Rhinitis | Phase 3 | Completed | - | - |
| NCT00779116 | - | Completed | - | - | |
| NCT02932774 | Allergic Rhinitis ... More >> Hay Fever SAR Rhinitis, Allergic, Seasonal Less << | Phase 4 | Completed | - | - |
| NCT03340740 | Allergic Rhinitis ... More >> Asthma Less << | Phase 4 | Recruiting | December 31, 2018 | United States, New York ... More >> Jacobi Medical Center Recruiting Bronx, New York, United States, 10461 Contact: Stephen Blumberg, MD 718-918-5826 stephen.blumberg@nychhc.org Contact: Katherine Huston, MD 718-918-5875 hustonk@nychhc.org Less << |
| NCT00779116 | Allergies | Phase 4 | Completed | - | - |
| NCT00794794 | Allergic Rhinitis | Phase 3 | Completed | - | - |
| NCT00780403 | - | Completed | - | - | |
| NCT00780403 | Allergies | Phase 4 | Completed | - | - |
| NCT00776139 | Healthy | Not Applicable | Completed | - | United States, Maryland ... More >> Bioanalytical Systems, Inc. Baltimore, Maryland, United States, 21201 Less << |
| NCT00794495 | Seasonal Allergic Rhinitis ... More >> Perennial Allergic Rhinitis Less << | Phase 4 | Completed | - | - |
| NCT00776022 | Healthy | Not Applicable | Completed | - | United States, Maryland ... More >> Bioanalytical Systems, Inc Baltimore, Maryland, United States, 21201 Less << |
| NCT00794599 | Seasonal Allergic Rhinitis ... More >> Perennial Allergic Rhinitis Less << | Phase 4 | Completed | - | - |
| NCT00863902 | Healthy | Phase 1 | Completed | - | United States, North Carolina ... More >> AAIPharma Inc.- AAI Clinic Morrisville, North Carolina, United States, 27560 Less << |
| NCT02132169 | Atopic Disease (Including Alle... More >>rgic Conjunctivitis) Less << | Phase 3 | Completed | - | United States, Massachusetts ... More >> Ora, Inc. Andover, Massachusetts, United States, 01810 Less << |
| NCT02132169 | - | Completed | - | - | |
| NCT01781507 | Allergic Rhinitis ... More >> Asthma Less << | Phase 4 | Completed | - | United States, California ... More >> California Allergy and Asthma Medical Group Los Angeles, California, United States, 90025 Less << |
| NCT03772158 | Allergy | Phase 1 | Recruiting | February 3, 2019 | Canada, Quebec ... More >> Algorithme (An altascience Company) Recruiting Mount-Royal, Quebec, Canada, H3P 3P1 Contact: Bich-Chau Le +1 (514) 858-6077 ext ext. 3236 Bich-Chau@altasciences.com Principal Investigator: Eric Sicard, MD Less << |
| NCT01064115 | Healthy | Phase 1 | Completed | - | - |
| NCT02865018 | Neuromyelitis Optica | Phase 1 Phase 2 | Completed | - | United States, New York ... More >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less << |
| NCT00864279 | Healthy | Phase 1 | Completed | - | United States, North Carolina ... More >> AAIPharma Inc.- AAI Clinic Morrisville, North Carolina, United States, 27560 Less << |
| NCT00794846 | Seasonal Allergic Rhinitis ... More >> Perennial Allergic Rhinitis Less << | Phase 4 | Completed | - | - |
| NCT01064102 | Healthy | Phase 1 | Completed | - | - |
| Bio Calculators | ||||
| Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.17mL 0.43mL 0.22mL |
10.83mL 2.17mL 1.08mL |
21.65mL 4.33mL 2.17mL |
|
| Dissolving Methods |
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
|
|||